Our vision is to improve patients’ quality of
life, globally, for those with vascular disease
through our pioneering technologies

Our Mission

OrbusNeich designs and delivers innovative solutions for the treatment of vascular disease that improve patients’ quality of life.

Our commitment is driven by Integrity, Passion, Innovation, and Performance. These respect the foundation of our core values that shape and reflect the company’s identity.

G-70-1095 Rev02


We are a global market leader in the development and manufacture of PCI/PTA balloons. Headquartered in Hong Kong, China, we sell products to over 70 countries and regions worldwide. In addition to PCI/PTA balloons, we also specialize in coronary stent products and are actively expanding into neuro vascular intervention and structural heart disease areas.

Our Group’s history traces back to 2000 when Mr. Teddy CHIEN, our Chairman Emeritus and founder, commenced our cardiovascular interventional medical devices business. Mr. Teddy CHIEN has worked with the medical community over the past 50 years in various capacities at pharmaceutical and medical device companies. Mr. Teddy CHIEN first launched Cordis Neich, an exclusive distributor of medical devices for diagnostics and interventional procedures for Cordis Corporation in Asia. After Cordis Corporation and assets of Cordis Neich were acquired by Johnson & Johnson in 1996, Mr. Teddy CHIEN founded our Group to focus on the development and manufacturing of endovascular interventional devices. Mr. Teddy CHIEN also established the Chien Foundation to provide young interventional cardiologists with financial resources and opportunities for training in enhanced techniques in interventional cardiology, with an overall objective to raise the standard of healthcare for the benefit of the general public in countries in Asia-Pacific region.

Under Mr. Teddy CHIEN’s leadership, we further expanded our research and development and manufacturing capacity in 2005 by acquiring Orbus Medical Technologies Inc., which primarily focuses on developing and manufacturing stents, by way of merger.

In 2016, Mr. David CHIEN became our CEO. Under his leadership, the Group has grown rapidly through market expansion, market penetration, enriching product offerings and venturing into new business segments. In 2021, the Group opened to third parties for investment for the first time and successfully raised over USD200 million of funds, marking a new chapter for its development.

G-70-1507 Rev02

Key Development Milestones

The following table sets forth certain key development milestones of our Group:




Our Group launched our R&D, product development and manufacturing base in Shenzhen, the PRC.

Our Group received our first regulatory approval for our balloon catheter from PMDA in September.


Our Group acquired Orbus Medical Technologies Inc. and its subsidiaries for a research and development center in the United States and a manufacturing base in the Netherlands, and expanded our sales network in Europe.


Our first generation “Sapphire” received CE Mark in April, marking the beginning of our Sapphire balloon catheter product family.


Our first generation “ScoreFlex” obtained CE Mark in May.


Mr. David CHIEN became our CEO, resetting the business strategy of our Group.

We launched our second generation COMBO Plus dual therapy stent with an advanced delivery system in June.


We commenced selling our balloon products in the United States.


Jade PTA received FDA 510(k) clearance in February.

Sapphire II Pro received FDA 510(k) clearance in March and became the first 1.0mm diameter balloon in the United States.

Teleport, our first microcatheter product, obtained CE Mark and FDA 510(k) clearance in March and November, respectively.

We commenced worldwide distribution of coronary artery and peripheral orbital atherectomy products for a United States medical device developer and manufacturer.


Our latest generation Sapphire 3 obtained approval from PMDA in January.

ScoreFlex PTA received FDA 510(k) clearance in May.

COMBO Plus dual therapy stent obtained approval from PMDA.


Sapphire 3 and Sapphire NC 24 received CE Mark in March.

We acquired our distributor in Switzerland in August to actively expand our direct sales network.

COMBO dual therapy stent obtained NMPA approval in August.

We formed a strategic joint venture with Products & Features International, LDA for  the  development, manufacturing and distribution of  structural heart products in certain countries in Asia Pacific regions in October.

Sapphire II Pro OTW version and Jade PTA 14”/18”/35” OTW series were launched in the United States.


We first opened to third party investments and completed two rounds of financing within a few months, raising US$202.5 million in aggregate from well-known institutional investors and family offices.

We expanded our direct sales network and established our direct sales team in China.

G-70-1508 Rev01

Executive Directors and Senior Management

David Chien

Chairman, Executive Director and CEO

Read more

Mr. David CHIEN (錢永勛) is the Chairman, Executive Director and CEO of OrbusNeich. Mr. Chien joined OrbusNeich in February 2000 and is primarily responsible for overseeing the overall strategic planning and policy execution of OrbusNeich.

Mr. Chien has around 27 years of experience in the medical device industry, and was the director of Cordis-Neich Limited from January 1994 to October 1997. He was a director of Tysan Holdings Limited, a company listed on the Stock Exchange (stock code: 0687), from November 1997 to January 2014. Mr. Chien has been the trustee of the Chien Foundation since January 1997 and the governor of KFoundation since July 2019. Mr. Chien was elected as a member of the Board of Trustees of Chung Chi College, the Chinese University of Hong Kong, in 2020.

Mr. Chien studied at York University in Canada.

Denise Lau

Executive Director and Chief Operating Officer

Read more

Ms. Kwai Ching Denise LAU (劉桂禎) is the Executive Director and Chief Operating Officer of OrbusNeich. She is primarily responsible for leading, overseeing and supervising the operation of OrbusNeich.

Ms. Lau has 21 years of legal, business operation and management experience. Ms. Lau was trained and admitted as a solicitor in Hong Kong in 1999, and was subsequently admitted to practice law in England and Wales and the state of New York in 2000 and 2001, respectively. She worked as an attorney in Paul, Weiss, Rifkind, Wharton & Garrison from 2000 to 2006 and joined Morgan Stanley in February 2006, and left as managing director in April 2015. She joined the Group as the general counsel on April 3, 2018, and has been the senior vice president since April 3, 2018.

Ms. Lau obtained her Bachelor of Law degree from The University of Hong Kong in 1996 and obtained her postgraduate certificate in law from the same university in 1997. Ms. Lau also obtained her Master’s degree in international  economic  law  from  the  University  of Warwick in the United Kingdom in January 2001.

Jason Chen

Executive Director and Chief Financial Officer

Read more

Mr. Wing Shing Jason CHEN (陳泳成) is the Executive Director and Chief Financial Officer of OrbusNeich.

Mr. Chen has over 18 years of experience in auditing, accounting and corporate finance. He joined PricewaterhouseCoopers in December 2003 in the assurance practice and left as senior manager in February 2017. Before joining OrbusNeich, Mr. Chen worked in corporate finance in the property development and investment sector in the PRC. Mr. Chen joined OrbusNeich in April 2017 as the financial controller and was later  promoted as the chief financial officer of OrbusNeich in January 2018.

Mr. Chen obtained his bachelor’s degree in business administration, concentrating in financial engineering from The Chinese University of Hong Kong with first class honors in December 2003. He is a certified public accountant in Hong Kong, the State of Washington and the State of Delaware, USA. He is also a charter holder of the Chartered Financial Analyst Institute.

John Chow

Executive Director and Head of Business Development

Read more

Mr. Ching Chung John CHOW (周靜忠) is the Executive Director and Head of Business Development of OrbusNeich, and is primarily responsible for overseeing overall business development activities of OrbusNeich.

Mr. Chow has over 36 years of experience in interventional cardiology. He worked in Cordis-Neich Limited in May 1984 and was promoted as the general manager in January 1991. Prior to joining OrbusNeich, he was appointed as the Asia Pacific regional marketing director of the Cordis franchise of Johnson & Johnson, in June 1999. After his employment at Johnson & Johnson, Mr. Chow joined OrbusNeich in August 2000 and served as the head of sales and marketing for the Asia Pacific region from 2010 to 2015. Mr. Chow was appointed as the director of business development of the Group on May 17, 2006.

Mr. Chow obtained his Bachelor of Arts degree from York University in Canada in June 1980.

Non Executive Director

Zhou Yi

Non-executive Director

Read more

Dr. Yi ZHOU (周伊) is a non-executive Director of OrbusNeich, primarily responsible for providing advice on the business development of OrbusNeich.

Dr. Zhou has over 14 years of research and working experience in the chemistry, pharmaceutical and biotechnology industries. He was an analyst in the pharmaceutical industry at Shenzhen Capital Group Co., Ltd. from May 2012 to September 2017. Since October 2017, Dr. Zhou has served as the head of department of the health industry fund in Shenzhen Capital Group Co., Ltd. Dr. Zhou has been a non-executive director of Akeso, Inc., a company listed on the Stock Exchange (stock code: 9926), since November 2019, and a director of Shenzhen YHLO Biotech Co., Ltd. (深圳市亞輝龍生物科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688575), since December 2016.

Dr. Zhou obtained his bachelor’s degree in chemistry from Hengyang Normal University in Hunan, the PRC in June 2003, his master ’s degree in organic chemistry from Hunan Normal University in Hunan, the PRC in July 2007, and his Ph.D. degree in medicinal chemistry from Peking University in the PRC in June 2011.

Senior Management

Robert Cottone, Jr.

Chief Technical Officer

Read more

Mr. Robert COTTONE JR is the chief technical officer of OrbusNeich, responsible for overseeing the overall technology and product research and development and the global intellectual property strategies and protection of OrbusNeich.

Mr. Cottone has more than 30 years of experience in the medical device field. Before joining our group, Mr. Cottone worked at the Cordis Corporation from 1989 to 1996. In 1997 Mr. Cottone co-founded Orbus Medical Technologies Inc., which was a longstanding partner of Neich Medical Limited and was subsequently acquired by Neich Medical Limited in 2005 and continued to work in OrbusNeich since our acquisition of Orbus Medical Technologies Inc.

Mr. Cottone obtained his Bachelor of Science degree from Florida International University in the United States of America in 1988.

Alain Khair

Chief Commercial Officer

Read more

Mr. Alain KHAIR is the chief commercial officer of OrbusNeich, responsible for overseeing global commercial activities and managing the development and the implementation of all commercial strategies. He also directs and oversees OrbusNeich’s growth matrix, distribution channels and the deployment of the company sales and marketing resources.

Mr. Khair has over 18 years of sales and marketing experience in the medical device industry.  He held several  management  roles including products  advisor,  territory sales manager, clinical specialist for Eastern Europe and Middle East at Abbott Laboratories Limited from 2003 to 2008. He joined OrbusNeich as regional product manager in January 2008 and was the vice president in sales of EMEA from May 1, 2017 to December 31, 2019.

Mr. Khair received his NMC registration in the United Kingdom in May  2002 and obtained his Master of Business Administration degree in marketing from University of Leicester in the United Kingdom in 2013.

G-70-1509 Rev01

Worldwide Locations

We have our research and development teams in both Shenzhen, China, and Florida, the United States, and our production facilities in Shenzhen, China, and Hoevelaken, the Netherlands.

OrbusNeich is represented throughout the world. Our Corporate Headquarters are located in Hong Kong. We have direct sales teams operating from China, Hong Kong, France, Germany, Japan, Malaysia, Singapore, Spain, and Switzerland and a distributor network covering over 70 countries and regions across six continents.

G-70-1510 Rev02

Headquarters, Research & Development and Production Facilities

Hong Kong, China

Corporate Headquarters

Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Shatin, N.T.
Hong Kong, China

Tel: +852 2802 2288
Fax: +852 2507 3532

Shenzhen, China

Production and Research
& Development Facility

Jinkui Road, Futian Free Trade Zone, Shenzhen, 518038, China


European Regional Headquarters
and Production Facility

Drs. W. van Royenstraat 5
3871 AN Hoevelaken
The Netherlands


Advanced Research & Development

5363 N.W. 35th Avenue
Ft. Lauderdale, FL 33309